{"id":"placebo-rosuvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Liver enzyme elevation"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting HMG-CoA reductase, Rosuvastatin reduces the liver's production of cholesterol, thereby lowering LDL cholesterol levels in the blood. This is particularly beneficial for patients with hypercholesterolemia or at risk of cardiovascular disease.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:22.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT05850091","phase":"PHASE4","title":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-07","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT07218900","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-13","conditions":"Dyslipidaemia","enrollment":76},{"nctId":"NCT06834932","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-06","conditions":"Dyslipidaemia","enrollment":360},{"nctId":"NCT06982131","phase":"PHASE1","title":"A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-04","conditions":"Overweight, Obesity","enrollment":40},{"nctId":"NCT04098003","phase":"PHASE4","title":"Investigation of the Gut Microbiome and Statin Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sony Tuteja","startDate":"2020-02-06","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT07232069","phase":"PHASE3","title":"PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-07-01","conditions":"Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control","enrollment":1500},{"nctId":"NCT05912387","phase":"EARLY_PHASE1","title":"Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-05-31","conditions":"Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06538649","phase":"EARLY_PHASE1","title":"Effect of Statins on Crohn's Disease","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-12-12","conditions":"Crohn's Ileocolitis, Crohn Disease","enrollment":20},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT06981299","phase":"PHASE1","title":"A Phase 1 Study of PROT-001.","status":"COMPLETED","sponsor":"Protego Biopharma Pty Ltd","startDate":"2025-05-29","conditions":"Healthy","enrollment":102},{"nctId":"NCT06772168","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia","status":"RECRUITING","sponsor":"CMG Pharmaceutical Co. Ltd","startDate":"2024-04-19","conditions":"Dyslipidemia, Type 2 Diabetes","enrollment":240},{"nctId":"NCT04319627","phase":"PHASE3","title":"Statins for Venous Event Reduction in Patients With Venous Thromboembolism","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-02-10","conditions":"Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome","enrollment":2700},{"nctId":"NCT05832229","phase":"PHASE2","title":"Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-12-07","conditions":"Cirrhosis, Cirrhosis, Liver, Cirrhosis Early","enrollment":256},{"nctId":"NCT03540355","phase":"PHASE3","title":"Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2021-03-02","conditions":"Dyslipidemias","enrollment":406},{"nctId":"NCT07303816","phase":"PHASE4","title":"Statins to Prevent Cancer Associated Blood Clots","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":"Venous Thromboembolism, Cancer, Cardiovascular Events","enrollment":4000},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT07254221","phase":"PHASE4","title":"Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shiraz University of Medical Sciences","startDate":"2026-02-01","conditions":"Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer","enrollment":400},{"nctId":"NCT03527069","phase":"PHASE3","title":"Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2021-01-29","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":146},{"nctId":"NCT04602754","phase":"PHASE3","title":"Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.","status":"RECRUITING","sponsor":"EMS","startDate":"2023-12-01","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":228},{"nctId":"NCT04883840","phase":"PHASE2, PHASE3","title":"Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-22","conditions":"Ulcerative Colitis","enrollment":177},{"nctId":"NCT07239414","phase":"PHASE3","title":"Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability","status":"NOT_YET_RECRUITING","sponsor":"Sohaib Ashraf","startDate":"2025-11-10","conditions":"Cardiovascular","enrollment":690},{"nctId":"NCT02117453","phase":"PHASE3","title":"Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10-27","conditions":"ANCA-associated Primary Necrotizing Vasculitides","enrollment":121},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT06603363","phase":"NA","title":"Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","status":"RECRUITING","sponsor":"Prof. Maurovich-Horvat Pál","startDate":"2025-05-28","conditions":"Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography","enrollment":140},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT05457582","phase":"NA","title":"PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-03-30","conditions":"Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention","enrollment":1212},{"nctId":"NCT05192941","phase":"PHASE4","title":"Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-04-08","conditions":"Hypercholesterolemia","enrollment":1776},{"nctId":"NCT06279234","phase":"PHASE1","title":"A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-20","conditions":"Type 2 Diabetes Mellitus (T2DM), Obesity","enrollment":50},{"nctId":"NCT07001787","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Dyslipidemia","enrollment":88},{"nctId":"NCT06048588","phase":"PHASE1, PHASE2","title":"YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Beijing Inno Medicine Co., Ltd.","startDate":"2023-10-08","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":144},{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT06924684","phase":"PHASE2","title":"High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2024-12-02","conditions":"ST Elevation (STEMI) Myocardial Infarction","enrollment":66},{"nctId":"NCT06594159","phase":"PHASE1","title":"A Study of LY4065967 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-10-22","conditions":"Healthy","enrollment":59},{"nctId":"NCT04542382","phase":"PHASE1","title":"Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-10-28","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT06804980","phase":"PHASE4","title":"DESIFOR-EXPAND (MHIF)","status":"RECRUITING","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2025-02-01","conditions":"Statin Therapy, Statin Adverse Reaction, Statin","enrollment":100},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06293261","phase":"","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-06-27","conditions":"Hypertension, Hypercholesterolemia","enrollment":5047},{"nctId":"NCT06036784","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects","status":"COMPLETED","sponsor":"MBX Biosciences","startDate":"2023-09-18","conditions":"Postbariatric Hypoglycemia","enrollment":69},{"nctId":"NCT04094519","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-01-27","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT05738291","phase":"PHASE1","title":"A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-05-01","conditions":"Healthy","enrollment":67},{"nctId":"NCT05384262","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-18","conditions":"Dyslipidemia","enrollment":183},{"nctId":"NCT02741245","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-06-09","conditions":"Hypercholesterolemia","enrollment":321},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT06371495","phase":"","title":"Statins Role in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-08-13","conditions":"Stroke, Acute","enrollment":105},{"nctId":"NCT02008786","phase":"PHASE4","title":"Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD","status":"TERMINATED","sponsor":"Cardiology Research UBC","startDate":"2014-06","conditions":"Coronary Artery Dissection, Spontaneous","enrollment":18},{"nctId":"NCT06304896","phase":"PHASE1","title":"Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Arab Contractors Medical Centre","startDate":"2024-05-01","conditions":"Chemotherapy Induced Systolic Dysfunction","enrollment":150},{"nctId":"NCT04931147","phase":"PHASE1","title":"A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-05-13","conditions":"Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis","enrollment":90},{"nctId":"NCT01011478","phase":"PHASE3","title":"Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2010-03","conditions":"Colorectal Cancer, Precancerous Condition","enrollment":406},{"nctId":"NCT04846231","phase":"PHASE2","title":"Supplements, Placebo, or Rosuvastatin Study","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-04-23","conditions":"Hypercholesterolemia","enrollment":203},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT02901067","phase":"PHASE2","title":"STAT-STatin and Aspirin in Trauma","status":"TERMINATED","sponsor":"Denver Health and Hospital Authority","startDate":"2017-02-03","conditions":"Wounds and Injuries, Venous Thromboembolism","enrollment":43},{"nctId":"NCT03907423","phase":"NA","title":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2019-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT00951132","phase":"PHASE2","title":"Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy","status":"WITHDRAWN","sponsor":"University Hospital, Akershus","startDate":"2009-09","conditions":"Depression","enrollment":""},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT02850081","phase":"PHASE3","title":"Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-06-01","conditions":"Carotid Artery Stenosis, Strokes","enrollment":31},{"nctId":"NCT04603508","phase":"PHASE3","title":"Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia","status":"UNKNOWN","sponsor":"EMS","startDate":"2023-03","conditions":"Type 2 Diabetes Mellitus, Dyslipidemia","enrollment":240},{"nctId":"NCT05373277","phase":"PHASE1","title":"KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2022-05-11","conditions":"Pharmacokinetics","enrollment":10},{"nctId":"NCT03847506","phase":"PHASE4","title":"Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-07-05","conditions":"Hypertension, Hyperlipidemia","enrollment":127},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT03889314","phase":"PHASE4","title":"The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial","status":"UNKNOWN","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2019-04-26","conditions":"Cardiovascular Risk Factor, Cardiovascular Diseases, Adverse Effect","enrollment":25},{"nctId":"NCT00651144","phase":"PHASE1","title":"Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":40},{"nctId":"NCT03009487","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-01","conditions":"Hypertension, Hyperlipidemias","enrollment":265},{"nctId":"NCT01425398","phase":"PHASE3","title":"A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2011-11","conditions":"Valvular Cardiac Surgery","enrollment":170},{"nctId":"NCT03113994","phase":"PHASE2","title":"Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk","status":"UNKNOWN","sponsor":"Dr. B. Catharine. Craven","startDate":"2018-02-26","conditions":"Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome","enrollment":8},{"nctId":"NCT02586155","phase":"PHASE3","title":"Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD","status":"COMPLETED","sponsor":"Resverlogix Corp","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":2425},{"nctId":"NCT02482207","phase":"PHASE4","title":"Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2015-11","conditions":"Hypertension","enrollment":96},{"nctId":"NCT01881971","phase":"EARLY_PHASE1","title":"Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center","status":"COMPLETED","sponsor":"Alison Morris","startDate":"2013-05","conditions":"HIV Seropositivity","enrollment":23},{"nctId":"NCT01813357","phase":"PHASE4","title":"Does Rosuvastatin Delay Progression of Atherosclerosis in HIV","status":"COMPLETED","sponsor":"Bayside Health","startDate":"2013-07-02","conditions":"HIV, Cardiovascular Disease","enrollment":84},{"nctId":"NCT01730053","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-11-30","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT04328064","phase":"NA","title":"The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2010-05","conditions":"Behcet's Disease","enrollment":56},{"nctId":"NCT02546323","phase":"PHASE3","title":"A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-17","conditions":"Atherosclerosis","enrollment":543},{"nctId":"NCT04161001","phase":"PHASE3","title":"Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-11-20","conditions":"Hypertension, Dyslipidemia","enrollment":237},{"nctId":"NCT00679510","phase":"PHASE2, PHASE3","title":"Rosuvastatin in Rheumatoid Arthritis (RORA)","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2004-02","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT03720067","phase":"PHASE2, PHASE3","title":"Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension","status":"UNKNOWN","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2019-01-25","conditions":"Cirrhosis, Portal Hypertension, Variceal Hemorrhage","enrollment":80},{"nctId":"NCT02072161","phase":"PHASE2","title":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":133},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT03874260","phase":"PHASE4","title":"Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy","status":"UNKNOWN","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2018-07-25","conditions":"Dyslipidemias","enrollment":180},{"nctId":"NCT01863914","phase":"PHASE2","title":"Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-11","conditions":"End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula","enrollment":60},{"nctId":"NCT02977065","phase":"PHASE2","title":"To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-03-23","conditions":"Dyslipidemias","enrollment":62},{"nctId":"NCT03677297","phase":"PHASE4","title":"\"Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects\"","status":"COMPLETED","sponsor":"Dr. D. Y. Patil Dental College & Hospital","startDate":"2016-01-28","conditions":"Adult Periodontitis","enrollment":10},{"nctId":"NCT03395470","phase":"PHASE1","title":"Safety, Tolerability and PK of PXL770 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2017-08-21","conditions":"Metabolic Disease","enrollment":60},{"nctId":"NCT03571087","phase":"PHASE3","title":"Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2014-09","conditions":"Primary Hypercholesterolemia","enrollment":374},{"nctId":"NCT01051401","phase":"PHASE1","title":"Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2010-01","conditions":"Cardiovascular Complications, Recurrent Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT01524653","phase":"PHASE2","title":"Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2012-03","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms","enrollment":38},{"nctId":"NCT03088254","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-09-20","conditions":"Dyslipidemia With Hypertension","enrollment":126},{"nctId":"NCT02827903","phase":"PHASE3","title":"Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-01-15","conditions":"Type 2 Diabetes, Dyslipidemia","enrollment":237},{"nctId":"NCT03566316","phase":"PHASE3","title":"Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-11-24","conditions":"Hypertension With Hyperlipidemia","enrollment":134},{"nctId":"NCT00978419","phase":"PHASE2","title":"Pilot Trial of Statin Use in Burn Patients","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-03","conditions":"Burns","enrollment":40},{"nctId":"NCT02546648","phase":"PHASE3","title":"PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study","status":"COMPLETED","sponsor":"McMaster University","startDate":"2015-02","conditions":"Atherosclerotic Disease, Perioperative Bleeding","enrollment":100},{"nctId":"NCT01105975","phase":"PHASE2","title":"A Study of LY2484595 in Patients With High LDL-C or Low HDL-C","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":"Dyslipidemia","enrollment":398},{"nctId":"NCT02434497","phase":"PHASE3","title":"A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-06","conditions":"Homozygous Familial Hypercholesterolemia (HoFH)","enrollment":9},{"nctId":"NCT00160745","phase":"PHASE2","title":"Rosuvastatin and Renal Endothelial Function","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"","conditions":"Hypercholesterolemia","enrollment":46},{"nctId":"NCT01699126","phase":"PHASE4","title":"The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2010-05","conditions":"Sleep Apnea, Obstructive","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo + Rosuvastatin","genericName":"placebo + Rosuvastatin","companyName":"Jeil Pharmaceutical Co., Ltd.","companyId":"jeil-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. Used for Hypercholesterolemia, Prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}